Articles
| Open Access |
https://doi.org/10.37547/ijmscr/Volume06Issue02-14
Analysis Of Clinical-Pharmacological Approaches To The Rational Use Of Drugs In Chronic Heart Failure
Abstract
Chronic heart failure (CHF) is a complex clinical syndrome with high morbidity and mortality. Rational pharmaceutical management is fundamental in improving symptoms, enhancing quality of life, and reducing hospitalizations and mortality. This article reviews current clinical-pharmacological strategies for CHF treatment, emphasizing evidence-based drug classes, therapeutic mechanisms, and rational prescription practices. Key drug categories include angiotensin-converting enzyme inhibitors (ACEIs), beta-adrenergic blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and diuretics. Additionally, new agents and optimization strategies are discussed. Flowcharts and diagrams illustrate treatment pathways and decision points. The analysis supports a patient-centered, risk-benefit approach to drug selection based on comorbidities, renal function, and individual tolerability.
Keywords
Chronic heart failure (CHF), pharmacological therapy, ACE inhibitors
References
McMurray JJ, Adamopoulos S, Anker SD, et al.
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. European Heart Journal. 2012;33(14):1787–1847.
Yancy CW, Jessup M, Bozkurt B, et al.
ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013;128:e240–e327.
Ponikowski P, Voors AA, Anker SD, et al.
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal. 2016;37(27):2129–2200.
Yancy CW, Januzzi JL, Allen LA, et al.
ACC/AHA/HFSA Focused Update on Heart Failure Management. Journal of the American College of Cardiology. 2017;70(6):776–803.
Packer M, McMurray JJ, Desai AS, et al.
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine. 2014;371:993–1004.
Zannad F, McMurray JJ, Krum H, et al.
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 2011;364:11–21.
Hauptman PJ, Kelly RA.
Heart Failure: Pharmacologic Therapies. In: Harrison’s Principles of Internal Medicine. 20th ed. McGraw-Hill Education; 2018.
McDonagh TA, Metra M, Adamo M, et al.
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal. 2021;42(36):3599–3726.
Anker SD, Butler J, Bakris GL, et al.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385:1451–1461.
Flather MD, Yusuf S, Køber L, et al.
Long-Term ACE Inhibitor Therapy in Patients with Heart Failure or Left Ventricular Dysfunction: A Systematic Overview of Data from Individual Patients. Lancet. 2000;355(9215):1575–1581.
CIBIS-II Investigators and Committees.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomized Trial. Lancet. 1999;353:9–13.
Gheorghiade M, Bonow RO.
Chronic Heart Failure in the United States: A Manifestation of Coronary Artery Disease. Circulation. 1998;97(3):282–289.
Vidović D, Škrabić V, Vrdoljak D.
Rational Drug Use in Heart Failure: What Every Clinician Should Know. Journal of Cardiological Pharmacology and Therapeutics. 2019;24(3):202–211.
Farmakis D, Parissis J, Lekakis J, et al.
Pathophysiology and Pharmacological Treatment of Acute Heart Failure. Cardiovascular Drugs and Therapy. 2010;24(4):315–327.
Gheorghiade M, Sopko G, De Luca L, et al.
Navigating the Crossroads of Heart Failure Care. European Journal of Heart Failure. 2013;15(7):679–680.
Article Statistics
Copyright License
Copyright (c) 2026 Agzamova Nazifa Valievna
This work is licensed under a Creative Commons Attribution 4.0 International License.